The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen

Emily J Henderson, Stephen R Lord, Jacqueline C T Close, Andrew D Lawrence, Alan Whone, Yoav Ben-Shlomo, Emily J Henderson, Stephen R Lord, Jacqueline C T Close, Andrew D Lawrence, Alan Whone, Yoav Ben-Shlomo

Abstract

Background: Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson's disease. The combined impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson's disease.

Methods/design: This is a single centre, double-blind, randomised placebo-controlled trial in 130 people with Hoehn and Yahr stage 2-3 idiopathic Parkinson's disease who have fallen in the past year. Participants will be randomised to two groups, receiving either rivastigmine capsules or identical placebo capsules for 8 months. Assessment will be undertaken at baseline and at the end of medication prescription (i.e. 8 months) with participants remaining enrolled in the trial for a further 4 months to monitor for falls and adverse events. The primary outcome is step time variability, assessed with and without the addition of concurrent cognitive tasks. Secondary outcomes will include other gait parameters, sensorimotor and balance performances, cognitive indices, falls and fall related injury, fear of falling, Parkinson's symptoms and data pertaining to possible harms.

Discussion: This randomised controlled trial will examine the effect of cholinesterase inhibitor therapy on gait, balance and falls in Parkinson's disease. If effective, it would offer a new therapeutic option to ameliorating gait and cognitive deficits in a population at high risk of falls.

Trial registration: ISRCTN19880883, UTN U1111-1124-0244.

Figures

Figure 1
Figure 1
Trial flow diagram.
Figure 2
Figure 2
Schedule of assessment visits, medication titration and monitoring of adverse events and falls.

References

    1. Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology. 2008;13:2241–2247. doi: 10.1212/01.wnl.0000313835.33830.80.
    1. Schenkman M, Cutson TM, Zhu CW, Whetten-Goldstein K. A longitudinal evaluation of patients’ perceptions of Parkinson’s disease. Gerontologist. 2002;13:790–798. doi: 10.1093/geront/42.6.790.
    1. Genever RW, Downes TW, Medcalf P. Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing. 2005;13:21–24. doi: 10.1093/ageing/afh203.
    1. Mak MKY, Pang MYC. Fear of falling is independently associated with recurrent falls in patients with Parkinson’s disease: a 1-year prospective study. J Neurol. 2009;13:1689–1695. doi: 10.1007/s00415-009-5184-5.
    1. Hely MA, Morris JGL, Traficante R, Reid WGJ, Sullivan DJO, Williamson PM. The Sydney multicentre study of Parkinson’ s disease: progression and mortality at 10 years. J Neurol. 1999;13:300–307.
    1. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006;13:35–41.
    1. Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, McKee A, Poewe W, Litvan I. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord. 1999;13:947–950. doi: 10.1002/1531-8257(199911)14:6<947::AID-MDS1006>;2-O.
    1. Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson’s disease? J Neurol. 2002;13:419–423. doi: 10.1007/s004150200032.
    1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;13:384–386. doi: 10.1212/01.wnl.0000247740.47667.03.
    1. Pickering RM, Grimbergen YAM, Rigney U, Ashburn A, Mazibrada G, Wood B, Gray P, Kerr G, Bloem BR. A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov Disord. 2007;13:1892–1900. doi: 10.1002/mds.21598.
    1. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;13:837–844. doi: 10.1002/mds.21956.
    1. Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson’s disease: frequency, impact and identifying factors. J Neurol. 2005;13:1310–1315. doi: 10.1007/s00415-005-0855-3.
    1. López IC, Ruiz PJG, Del Pozo SVF, Bernardos VS. Motor complications in Parkinson’s disease: ten year follow-up study. Mov Disord. 2010;13:2735–2739. doi: 10.1002/mds.23219.
    1. Karachi C, Grabli D, Bernard FA, Tande D, Wattiez N, Belaid H, Bardinet E, Prigent A, Nothacker H-P, Hunot S, Hartmann A, Lehericy S, Hirsch EC, Francois C. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest. 2010;13:2745–2754. doi: 10.1172/JCI42642.
    1. Bohnen NI, Muller MLTM, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;13(20):1670–1676. doi: 10.1212/WNL.0b013e3181c1ded6.
    1. Rinne JO, Ma SY, Lee MS, Collan Y, Röyttä M. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson’s disease is related to disability of the patients. Parkinsonism Relat Disord. 2008;13:553–557. doi: 10.1016/j.parkreldis.2008.01.006.
    1. Lawrence AD, Sahakian BJ. Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord. 1995;13(2):37–49.
    1. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;13:349–356. doi: 10.1002/mds.24893.
    1. Nakano I, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol. 2004;13(5):415–418.
    1. Jellinger K. The morphological basis of mental dysfunction in Parkinson’s disease. J Neurol Sci. 2006;13:167–172. doi: 10.1016/j.jns.2006.05.002.
    1. Hilker R, Thomas A, Klein J. Dementia in Parkinson disease functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;13:1716–1722. doi: 10.1212/01.wnl.0000191154.78131.f6.
    1. Kahneman D. Attention and effort, Volume 88. Englewood Cliffs, NJ: Prentice-Hall; 1973.
    1. Kelly V, Eusterbrock A, Shumway-Cook A. A review of dual-task walking deficits in people with Parkinson’s disease: motor and cognitive contributions, mechanisms, and clinical implications. Park Dis. 2012;13:918719.
    1. Bloem BR, Grimbergen YAM, van Dijk JG, Munneke M. The “posture second” strategy: a review of wrong priorities in Parkinson’s disease. J Neurol Sci. 2006;13:196–204. doi: 10.1016/j.jns.2006.05.010.
    1. Montero-Odasso M. Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J Am Geriatr Soc. 2009;13:359–360. doi: 10.1111/j.1532-5415.2009.02085.x.
    1. Assal F, Allali G. Galantamine improves gait performance in patients with Alzheimer’s disease. J Am Geriatr Soc. 2008;13:946–947. doi: 10.1111/j.1532-5415.2008.01657.x.
    1. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. 2010;13:1263–1269. doi: 10.1212/WNL.0b013e3181f6128c.
    1. Montero-Odasso M, Wells JL, Borrie MJ, Speechley M. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. BMC Neurol. 2009;13:42. doi: 10.1186/1471-2377-9-42.
    1. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;13:385–397. doi: 10.1007/s00198-007-0543-5.
    1. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012;13:e3427. doi: 10.1136/bmj.e3427.
    1. Rockwood K, Song X, Macknight C, Bergman H, Hogan DB, Mcdowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. Can Med J. 2005;13:489–495. doi: 10.1503/cmaj.050051.
    1. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;13:M146–M157. doi: 10.1093/gerona/56.3.M146.
    1. Washburn R, Smith K, Jette A, Janney C. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;13:153–162. doi: 10.1016/0895-4356(93)90053-4.
    1. Schrag A, Selai C. The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol. 2000;13:67–73.
    1. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY. A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Mov Disord. 2010;13:2501–2507. doi: 10.1002/mds.23362.
    1. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982;13:1–16. doi: 10.1111/j.2044-8260.1982.tb01421.x.
    1. Brown J, Pengas G, Dawson K. Self administered cognitive screening test (TYM) for detection of Alzheimer’s disease: cross sectional study. BMJ. 2009;13:b2030. doi: 10.1136/bmj.b2030.
    1. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB A frontal assessment battery at bedside. Neurology. 2000;13(11):1621–1626. doi: 10.1212/WNL.55.11.1621.
    1. Meara J, Mitchelmore E, Hobson P. GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson’s disease and their carers in the community. Age Ageing. 1999;13:35–38. doi: 10.1093/ageing/28.1.35.
    1. Nieuwboer A, Rochester L, Herman T, Vandenberghe W, Emil GE, Thomaes T, Giladi N. Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson’s disease and their carers. Gait Posture. 2009;13:459–463. doi: 10.1016/j.gaitpost.2009.07.108.
    1. Lord S, Ward J, Williams P. Exercise effect on dynamic stability in older women: a randomized controlled trial. Arch Phys Med Rehabil. 1996;13(March):232–236.
    1. Lord S, Menz H, Tiedemann A. A physiological profile approach to falls risk assessment and prevention. Phys Ther. 2003;13:237–252.
    1. Paul SS, Canning CG, Sherrington C, Lord SR, Close JCT, Fung VSC. Three simple clinical tests to accurately predict falls in people with Parkinson’s disease. Mov Disord. 2013;13:655–662. doi: 10.1002/mds.25404.
    1. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;13:2129–2170. doi: 10.1002/mds.22340.
    1. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin SLR. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;13:2509–2518. doi: 10.1056/NEJMoa041470.
    1. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo J-M, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;13:501–512. doi: 10.1016/S1474-4422(07)70109-6.
    1. Hausdorff JM. Gait variability : methods, modeling and meaning. J Neuroeng Rehabil. 2005;13:19. doi: 10.1186/1743-0003-2-19.
    1. Latt MD, Lord SR, Morris JGL, Fung VSC. Clinical and physiological assessments for elucidating falls risk in Parkinson’s disease. Mov Disord. 2009;13:1280–1289. doi: 10.1002/mds.22561.
    1. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;13:1717–1725. doi: 10.1212/WNL.0b013e3181fc29c9.
    1. Delbaere K, Smith ST, Lord SR. Development and initial validation of the iconographical falls efficacy scale. J Gerontol A Biol Sci Med Sci. 2011;13:674–680.
    1. Lamb SE, Jørstad-Stein EC, Hauer K, Becker C. Development of a common outcome data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus. J Am Geriatr Soc. 2005;13:1618–1622. doi: 10.1111/j.1532-5415.2005.53455.x.
    1. Maki BE. Gait changes in older adults: predictors of falls or indicators of fear. J Am Geriatr Soc. 1997;13:313–320.
    1. Hausdorff JM, Balash J, Giladi N. Effects of cognitive challenge on Gait variability in patients with Parkinson’s disease. J Geriatr Psychiatry Neurol. 2003;13:53–58.
    1. Robertson MC, Campbell AJ, Herbison P. Statistical analysis of efficacy in falls prevention trials. J Gerontol A Biol Sci Med Sci. 2005;13:530–534. doi: 10.1093/gerona/60.4.530.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅